1. www.cymru.gov.uk NISCHR Academic Health Science Collaboration Launch Millennium Stadium Cardiff 3 March 2011

2. www.cymru.gov.uk Professor Mark Rees, Professor of Molecular Neuroscience and Research, Director of ILS, Swansea University Opportunities at The Institute of Life Sciences (ILS)

3.  2001: Wales’ newest Clinical School is commissioned  2003: Plans for the ILS-1 begin  2005: Work starts on the building  2007: ILS Phase One opens for business  2008: School of Medicine gains independent status  2008: Centre for NanoHealth announced  2009: ILS Phase-2 announced  2010: School granted College Status by SU  2011: ILS Phase-2 will open for business in November Overview

4. 400 doctors qualified or in training 200 Welsh companies directly assisted 50+ research collaborations with industry and business 220 new jobs created 30 new companies established in the sector >11,000 square metres for research and business incubation Exclusive ‘soft-landing’ Affiliate scheme Nearly £20 million investment triggered UK Centre for Mass Spectrometry 85% of research international standard or above Progress to Date

5. Outline of ILS-1 Floor 5: Medical Microbiology & Centre for P450 Research Floor 4: Cell Biology in Cancer and Reproductive Disorders Floor 3: Neurology and Diabetes Research Floor 2: Allergy & Immunity and Commercial Lab Space Floor 1: Bioinformatics, Genetics, Business & Innovation Office Ground Floor: Business Incubation Space

6. Outline of ILS Activity ILS-1: Biomedical Science and Innovation Centre UK Centre for Mass Spectrometry Centre for Informatics, Health Research and Evaluation (CHIRAL) Themes: Diabetes, Emergency Care, Gastroenterology, Mental Health, Injury and Environment Research, HIRU Methodologies: SAIL Database, Health and Bioinformatics, Population Studies, Health Services Research, Qualitative Health, Clinical Trails Unit and Complex Interventions

7. 4 star World Leading 3 star Internationally Leading 2 star International Quality 1 star UK 20%35%30%15% Research Assessment Exercise 2008 85% of College of Medicine research judged as international quality 55% is Internationally or World Leading

8. College of Medicine Research Income 2006-2010

9. Doing Business

10. ILS-1 Client SME’s Calon Cymru Ltd: Next generation of implantable micro-pump for the treatment of heart failure in phase 1 trials. Seren Technology Ltd: Oxygen based therapies for skin care and wound healing. Maimonidex Ltd: Treatment of Rheumatoid Arthritis with immuo-therapeutic antibodies. Vikel Ltd: Community-based hypertonicity seizure monitors. Allerna Ltd: A drug development company using RNA-based suppression to prevent asthmatic and allergic reactions.

11. Actual % of target achieved New jobs created207105 Companies advised in R&D/Innovation 135102 New companies created22105 Increase in turnover£14.71m101 Collaborative research projects32112 New patents/trademarks20110 Output Deliverables of ILS-1 Institute of Life Science Phase One: Audited figures reported to WEFO February 2009

12. Institute of Life Science Phase Two Centre for NanoHealth™ Clinical Research Facility Health Services Research Business Incubation Advanced Medical Imaging Mass Spectrometry Investment View of ILS Phase Two from Swansea University

13. Actual % of target achieved Phase Two Forecast to 2012 New jobs created207105607 Companies advised in R&D/Innovation 135102435 New companies created2210532 Increase in turnover£14.71m101£34.71m Collaborative research projects3211262 New patents/trademarks2011035 Track Record Institute of Life Science Phase One: Audited figures reported to WEFO February 2009

14. Centre for NanoHealth™ £22M open access R&D facility based in a hospital environment Assist and collaborate with companies in developing novel products + processes Class 100/1000 clean room and Bio-clean room Direct access to Clinical Trials Unit & Patient Imaging (MRI&CT) NMR & Rheology Printing and Coating NanoToxicology Nanostructure growth & probe Unique interdisciplinary R&D environment, based on the application of Nanotechnology, leading innovations in Healthcare Cell Imaging Tissue Engineering Molecular biology Microbiology

15. Clinical Research Facility

16. Advanced Medical Imaging CT Definition AS Research Based Platform Co-located to NHS Fully Configured Supportive of ILS-2 modules Project Portfolio

17. My Thanks

18. New Client Companies Siemens Research Collaboration SME interaction, POWYS Scholarships, Academic network support Novo Nordisk and Sugar Labs Comprehensive nutritional testing service to determine glycaemic index of foodstuffs or fluid product. 25 Affiliate Companies asking for units and space Arcis Biotechnology Ltd Specialise in the manufacture of new technology-based, antimicrobial products. Fulcrum Direct A marketing and business consultancy, specialising in the biotech and life sciences markets. Haemair Ltd Patented technology for a ‘Blood / Air Mass Exchanger’ for prosthetic (artificial lung) or external use.

19. ILS-1 and ILS-2 Summary The ILS concept is the research arm of the College of Medicine represents a significant increase in research capacity in Wales. It is driving the clinical and research priorities as established in the Wales Science Plan. ILS is open for business and can provide assistance through dedicated business innovation teams. This is supported by the academic staff led by 32 Professoriate teams across many of the clinical and scientific disciplines.

20. My Thanks Academic Members of ILS ILS Business Innovation team Client Businesses Professor Julian Hopkins CBE Professor Marc Clement, VC University of Wales